复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02696 复宏汉霖

未开盘 03-19 16:08:15

65.300

-1.400

-2.10%

最高66.700	最低64.550	成交量28.61万
今开66.700	昨收66.700	日振幅3.22%
总市值354.58亿	流通市值225.99亿	总股本5.43亿
成交额1,860万	换手率0.08%	流通股本3.46亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02696","market":"HK","secType":"STK","nameCN":"复宏汉霖","latestPrice":65.3,"timestamp":1773907695003,"preClose":66.7,"halted":0,"volume":286080,"delay":0,"changeRate":-0.020989505247376396,"floatShares":346074397,"shares":543000000,"eps":1.7187750293064683,"marketStatus":"未开盘","change":-1.4,"latestTime":"03-19 16:08:15","open":66.7,"high":66.7,"low":64.55,"amount":18604565,"amplitude":0.032234,"askPrice":65.3,"askSize":2600,"bidPrice":65.1,"bidSize":200,"shortable":3,"etf":0,"ttmEps":1.726790418766794,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773970200000},"marketStatusCode":0,"adr":0,"listingDate":1569340800000,"exchange":"SEHK","adjPreClose":66.7,"openAndCloseTimeList":[[1773883800000,1773892800000],[1773896400000,1773907200000]],"volumeRatio":0.5923062301243107,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02696","defaultTab":"news","newsList":[{"id":"2620970240","title":"对话复宏汉霖朱俊：AI在药品研发中非常值得用，最终目标是没有实验室","url":"https://stock-news.laohu8.com/highlight/detail?id=2620970240","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620970240?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:14","pubTimestamp":1773922440,"startTime":"0","endTime":"0","summary":"　　3月19日消息，2026亚布力论坛年会于3月17日-19日在黑龙江亚布力举办。新浪财经对话复宏汉霖首席执行官朱俊。谈到AI，朱俊坦言，复宏汉霖非常拥抱AI，现在要求每个高管都要养“龙虾”，他自己也在养。他谈到，复宏汉霖的管理层已经尝试了两个月，已经使用得很好。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-19/doc-inhrpsps4589740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02696","HK0000306685.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2620643287","title":"复宏汉霖朱俊阐释做药企“第一性原理”：敢解决别人不敢解决的问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2620643287","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620643287?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:54","pubTimestamp":1773816840,"startTime":"0","endTime":"0","summary":"　　2026亚布力论坛年会于3月17日-19日在黑龙江亚布力举办。复宏汉霖首席执行官朱俊出席并演讲。他坦言，“可能因为我们做的很多东西有一些叛逆性，但是又不失第一性原理。”　　他进一步解释到，所谓第一性原理，首先，就是不管风险高不高，只看你发的这个愿，到底能不能解决一些可能其他暂时还不敢解决的问题。朱俊表示，复宏汉霖非常拥抱AI，来提高工作效率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-03-18/doc-inhrkwsr7500483.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02696","HK0000165453.HKD","HK0000320223.HKD","HK0000306685.HKD","HK0000306701.USD","HK0000320264.USD"],"gpt_icon":0},{"id":"2620301411","title":"上药控股与复宏汉霖签约 将在创新药产品领域开展深度战略协作","url":"https://stock-news.laohu8.com/highlight/detail?id=2620301411","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620301411?lang=zh_cn&edition=full","pubTime":"2026-03-17 10:07","pubTimestamp":1773713279,"startTime":"0","endTime":"0","summary":"人民财讯3月17日电，3月16日，上药控股与复宏汉霖举行战略合作签约仪式，双方将重点拓展并深化医院市场开发与国际业务合作，特别是在创新药产品领域开展深度战略协作，通过优势互补充分释放协同潜力，共同提升医疗可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603173674239314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02696","HK0000306685.HKD","06978","HK0000306701.USD","BK1161","HK0000320223.HKD","159992","HK0000320264.USD","HK0000165453.HKD","BK1574"],"gpt_icon":0},{"id":"2620241656","title":"港股公告掘金 | 蚂蚁集团收购耀才证券金融的要约已获批准 3月17日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241656","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620241656?lang=zh_cn&edition=full","pubTime":"2026-03-17 09:04","pubTimestamp":1773709477,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"808c1f0b8ebd0042a82fe4057566a434","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06688","01276","LU1023057109.AUD","BK1521","BK1191","BK4588","HK0000306685.HKD","HK0000320264.USD","LU0359202008.SGD","BK1515","01428","BK1161","BK1606","BK4585","LU2543165471.USD","HK0000165453.HKD","LU0359201885.HKD","HK0000306701.USD","02565","LU0359201612.USD","VXUS","BK1147","00874","02696","BK1197","HK0000320223.HKD"],"gpt_icon":1},{"id":"2619459305","title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459305","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619459305?lang=zh_cn&edition=full","pubTime":"2026-03-16 17:45","pubTimestamp":1773654338,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近日，本公司自主研发的pimurutamab HLX07(重组抗EGFR人源化单克隆抗体注射液)(HLX07)联合汉斯状®(斯鲁利单抗注射液)(汉斯状®)和化疗治疗晚期鳞状非小细胞肺癌(sqNSCLC) 的临床试验申请获国家药品监督管理局(NMPA)批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状®和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02696","HK0000165453.HKD","HK0000306701.USD","BK1161","HK0000320223.HKD","HK0000320264.USD","HK0000306685.HKD"],"gpt_icon":0},{"id":"2618924894","title":"每日卖空追踪 | 复宏汉霖 03月11日卖空量成交8700股，卖空比例为4.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924894","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924894?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:30","pubTimestamp":1773217833,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间03月11日，跌0.94%，卖空量成交8700股，较上一交易日减少93.98%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163452a6b795d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311163452a6b795d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000306685.HKD","02696","BK1161","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD"],"gpt_icon":0},{"id":"2618692484","title":"复宏汉霖PD-L1 ADC启动全球II/III期关键研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692484","media":"医药魔方Info","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618692484?lang=zh_cn&edition=full","pubTime":"2026-03-11 12:25","pubTimestamp":1773203156,"startTime":"0","endTime":"0","summary":"3月10日，美国临床试验收录网站显示，复宏汉霖启动了HLX43治疗鳞状非小细胞肺癌的II/III期研究。这是该药物启动的首项II/III期临床试验。HLX43是复宏汉霖基于宜联生物技术平台开发的一款PD-L1 ADC，其有效载荷为拓扑异构酶I抑制剂，DAR值为8。临床前研究显示，HLX43在PD-1/PD-L1单抗耐药的非小细胞肺癌、宫颈癌、食管鳞癌等多个瘤种中展现出治疗潜力，且耐受性良好。2025年11月，复宏汉霖公布了HLX43-FIH101及HLX43-NSCLC201两项临床研究的合并分析数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311122920a6b70a31&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000306701.USD","HK0000306685.HKD","02696","BK1161","HK0000165453.HKD","HK0000320223.HKD","HK0000320264.USD"],"gpt_icon":0},{"id":"2618120995","title":"同一日，康宁杰瑞、复宏汉霖等多家药企创新药迎来临床新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2618120995","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618120995?lang=zh_cn&edition=full","pubTime":"2026-03-10 16:29","pubTimestamp":1773131340,"startTime":"0","endTime":"0","summary":"3月9日，康宁杰瑞、复宏汉霖、康方生物等多家药企创新药临床获新进展，覆盖多治疗领域，展现中国创新药研发实力。其中，康宁杰瑞登记了JSKN016的临床III期研究，预计招募364例三阴性乳腺癌患者，JSKN016是靶向TROP2和HER3双抗ADC，可发挥肿瘤杀伤作用；康方生物注射用AK150首次获批临床，用于治疗晚期实体瘤，依托AI制药与多抗技术平台研发，可同时调节先天和获得性免疫系统；科伦博泰与和铂医药共同申报的SKB575注射液获批临床，用于治疗特应性皮炎，是超长效靶向TSLP的双抗。此外，复宏汉霖DLL3xDLL3xCD3xCD28四特异性抗体药也有新进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310164215a45e0020&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310164215a45e0020&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","HK0000320264.USD","HK0000306701.USD","06978","HK0000320223.HKD","HK0000165453.HKD","BK1574","HK0000306685.HKD"],"gpt_icon":0},{"id":"2618607592","title":"港股异动 | 复宏汉霖(02696)再涨超8% B7-H3唾液酸酶融合蛋白HLX316临床研究申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2618607592","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618607592?lang=zh_cn&edition=full","pubTime":"2026-03-10 11:10","pubTimestamp":1773112220,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖再涨超8%，截至发稿，涨5.08%，报69.3港元，成交额3373.1万港元。消息面上，3月9日，中国国家药监局药品审评中心官网公示显示，复宏汉霖1类新药注射用HLX316获批临床，拟开发治疗晚期/转移性实体瘤。公开资料显示，这是一款B7H3-唾液酸酶融合蛋白。截至本公告日期，于全球范围内尚无靶向B7-H3的唾液酸酶Fc融合蛋白获批上市。此外，2026年欧洲肺癌大会将于当地时间3月25日至28日在丹麦哥本哈根举行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000306701.USD","BK1161","BK4588","HK0000165453.HKD","02696","HK0000320223.HKD","VXUS","HK0000306685.HKD","BK4585"],"gpt_icon":0},{"id":"2618995124","title":"复宏汉霖盘中异动 股价大涨5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618995124","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618995124?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:37","pubTimestamp":1773106633,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时37分，复宏汉霖股票出现波动，股价大幅拉升5.69%。截至发稿，该股报69.700港元/股，成交量4.55万股，换手率0.01%，振幅3.34%。资金方面，该股资金流入294.05万港元，流出12.985万港元。复宏汉霖股票所在的生物技术行业中，整体涨幅为1.93%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310093714a45ce75a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310093714a45ce75a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD","HK0000320264.USD","BK1161","HK0000165453.HKD"],"gpt_icon":0},{"id":"2618646918","title":"复宏汉霖(02696)：HLX3901注射液(DLL3xDLL3xCD3xCD28四特异性抗体)在晚期/转移性实体瘤患者中的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618646918","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618646918?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:31","pubTimestamp":1773045119,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖(02696)发布公告，近 日 ， HLX3901 注射液(DLL3xDLL3xCD3xCD28四特异性抗体)在晚期/转移性实体瘤患者中的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411601.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"复宏汉霖(02696)：HLX3901注射液(DLL3xDLL3xCD3xCD28四特异性抗体)在晚期/转移性实体瘤患者中的临床试验申请获国家药品监督管理局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","HK0000306701.USD","HK0000320223.HKD","BK1161","HK0000306685.HKD","HK0000165453.HKD","02696"],"gpt_icon":0},{"id":"2618781176","title":"每日卖空追踪 | 复宏汉霖 03月09日卖空量成交14.8万股，卖空比例为7.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618781176","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618781176?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045033,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间03月09日，跌4.42%，卖空量成交14.8万股，较上一交易日增加8.35%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163447a6b1c86a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163447a6b1c86a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK1161","HK0000306685.HKD","HK0000320264.USD","HK0000165453.HKD","HK0000320223.HKD","HK0000306701.USD"],"gpt_icon":0},{"id":"2618125678","title":"复宏汉霖盘中异动 早盘大幅跳水5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618125678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618125678?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:31","pubTimestamp":1773019912,"startTime":"0","endTime":"0","summary":"2026年03月09日早盘09时31分，复宏汉霖股票出现波动，股价大幅下跌5.07%。截至发稿，该股报65.500港元/股，成交量1.64万股，换手率0.00%，振幅3.12%。机构评级方面，在所有3家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。复宏汉霖股票所在的生物技术行业中，整体跌幅为2.03%。复宏汉霖公司简介：上海复宏汉霖生物技术股份有限公司是一家主要从事单克隆抗体产品的研发、生产及销售业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093152a6b0835b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309093152a6b0835b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320223.HKD","HK0000306685.HKD","02696","HK0000165453.HKD","HK0000320264.USD","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"2617066845","title":"创新药板块强势 三生制药(01530)涨9.83% 机构指业绩兑现有望催化板块行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066845","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066845?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:41","pubTimestamp":1772764875,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药板块强势，三生制药 涨9.83%，基石药业-B涨6.84%，荣昌生物涨6.31%，映恩生物-B涨5.98%，四环医药涨5.76%，恒瑞医药涨5.77%，君圣泰医药-B涨5.58%，康诺亚-B涨5.31%，复宏汉霖涨5.02%。交银国际表示，本周各公司业绩预告陆续发布，该机构建议持续关注财务表现超预期、盈利路径清晰的公司，其业绩兑现有望催化板块行情。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976042","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696","09995","HK0000252160.HKD","BK1600","BK1515","BK1574","01276","BK1583","HK0000500386.USD","LU2543165471.USD","01530","LU0359202008.SGD","LU2328871848.SGD","06978","02162","00460","HK0000252152.HKD","HK0000306701.USD","LU1969619763.USD","02511","02616","LU0359201612.USD","159992","HK0000306685.HKD","BK1191","HK0000320264.USD","HK0000320223.HKD","LU0359201885.HKD","LU1023057109.AUD","09606","BK1161","BK1587","HK0000165453.HKD","BK1593"],"gpt_icon":0},{"id":"2617150523","title":"港股异动 | 复宏汉霖(02696)涨超5% 自研KAT6A/B小分子抑制剂HLX97获国家药监局IND许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2617150523","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617150523?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:10","pubTimestamp":1772763011,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复宏汉霖(02696)涨超5%，截至发稿，涨5.02%，报68港元，成交额1948.15万港元。消息面上，3月5日，复宏汉霖发布公告，近日，本公司自主研发的HLX97(KAT6A/B小分子抑制剂)(HLX97)在晚期/转移性实体瘤患者中的1期临床试验申请(IND)获国家药品监督管理局(NMPA)批准。HLX97是本公司自主研发的赖氨酸乙酰转移酶6A/B(KAT6A/B)小分子抑制剂，拟用于治疗晚期/转移性实体瘤。非临床研究显示， HLX97可抑制KAT6A/B的活性，具有良好的抗肿瘤效果和安全性特征。截至本公告日，于全球范围内尚无KAT6A/B小分子抑制剂获批上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000320264.USD","BK1161","VT","IND","HK0000165453.HKD","BK4588","HK0000320223.HKD","VXUS","HK0000306701.USD","02696","BK4585","HK0000306685.HKD"],"gpt_icon":0},{"id":"2617254829","title":"全球尚无同类产品：复宏汉霖HLX97临床试验获批 靶向晚期/转移性实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2617254829","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617254829?lang=zh_cn&edition=full","pubTime":"2026-03-05 18:01","pubTimestamp":1772704905,"startTime":"0","endTime":"0","summary":"3月5日，复宏汉霖（02696）发布公告，公司自主研发的HLX97（KAT6A/B小分子抑制剂）在晚期/转移性实体瘤患者中的1期临床试验申请获得国家药品监督管理局批准。HLX97旨在治疗晚期/转移性实体瘤，具有良好的抗肿瘤效果和安全性特征。截至公告日，全球范围内尚无KAT6A/B小分子抑制剂获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603053663266538.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["HK0000306685.HKD","02696","BK1161","HK0000320223.HKD","HK0000165453.HKD","HK0000306701.USD","HK0000320264.USD"],"gpt_icon":0},{"id":"1171280574","title":"复宏汉霖HLX97（Kat6a/B小分子抑制剂）临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1171280574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171280574?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:32","pubTimestamp":1772703177,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司宣布，其自主研发的HLX97（一种针对Kat6a/B的小分子抑制剂）临床试验申请，已获得国家药品监督管理局（NMPA）的正式批准。\n此次获批标志着该创新药物将进入临床开发阶段，为公司肿瘤治疗领域的管线增添了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","HK0000165453.HKD","BK1161","HK0000320264.USD","HK0000306701.USD","02696","HK0000320223.HKD"],"gpt_icon":0},{"id":"1189551758","title":"复宏汉霖（02696）2月股份变动月报表：H股转增182,645,856股","url":"https://stock-news.laohu8.com/highlight/detail?id=1189551758","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189551758?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:11","pubTimestamp":1772619108,"startTime":"0","endTime":"0","summary":"上海复宏汉霖生物技术股份有限公司于2026年3月4日发布截至2026年2月28日的股份变动月报表。报告显示，本月公司依法完成非上市股份向H股的转换，使H股股本大幅增加。，公司公告披露，H股（普通股）期初数量为163,428,541股，因将182,645,856股非上市股份转为H股后，期末达到346,074,397股；非上市股份则由380,066,312股减少至197,420,456股。整体注册股本由上月合计543,494,853股维持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02696"],"gpt_icon":0},{"id":"2617506435","title":"复宏汉霖潜在 best-in-class 小分子新药首次获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2617506435","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617506435?lang=zh_cn&edition=full","pubTime":"2026-03-04 18:01","pubTimestamp":1772618463,"startTime":"0","endTime":"0","summary":"3 月 4 日，CDE 官网显示，复宏汉霖HLX97 临床试验申请获得批准，用于治疗晚期/转移性实体瘤。这是第 3 款获批临床的国产 KAT6A/B 抑制剂。来源：CDE 官网HLX97 是一款新型、潜在同类最优的口服组蛋白乙酰转移酶抑制剂。KAT6A/B 是乳腺癌等实体瘤治疗中极具潜力的靶点，其异常与多种血液肿瘤和实体瘤的发生发展密切相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030419342297a805ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030419342297a805ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","HK0000320223.HKD","02696","HK0000320264.USD","HK0000306685.HKD","HK0000306701.USD","BK1161"],"gpt_icon":0},{"id":"2617555067","title":"每日卖空追踪 | 复宏汉霖 03月04日卖空量成交2.92万股，卖空比例为2.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617555067","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617555067?lang=zh_cn&edition=full","pubTime":"2026-03-04 16:30","pubTimestamp":1772613033,"startTime":"0","endTime":"0","summary":"复宏汉霖北京时间03月04日，涨0.16%，卖空量成交2.92万股，较上一交易日减少62.27%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163449a6a1502e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260304163449a6a1502e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","HK0000165453.HKD","02696","HK0000320264.USD","HK0000320223.HKD","HK0000306701.USD","HK0000306685.HKD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0347},{"period":"1month","weight":-0.0738},{"period":"3month","weight":0.044},{"period":"6month","weight":-0.1585},{"period":"1year","weight":1.1587},{"period":"ytd","weight":0.1446}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0074},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0294},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海复宏汉霖生物技术股份有限公司是一家主要从事生物制药研发、生物制药服务及生物制药生产与销售的中国公司。该公司的主要产品包括汉曲优（注射用曲妥珠单抗）、汉奈佳（马来酸奈拉替尼片）、汉斯状（斯鲁利单抗注射液）、汉利康（利妥昔单抗注射液）、汉达远（阿达木单抗注射液）、汉贝泰（贝伐珠单抗注射液）等。该公司的产品主要应用于乳腺癌辅助治疗、转移性乳腺癌及转移性胃癌治疗、转移性非鳞状非小细胞肺癌、多关节型幼年特发性关节炎治疗等。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.044394},{"month":2,"riseRate":0.714286,"avgChangeRate":0.117695},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.018296},{"month":4,"riseRate":0.833333,"avgChangeRate":0.128587},{"month":5,"riseRate":0.5,"avgChangeRate":-0.024483},{"month":6,"riseRate":0.666667,"avgChangeRate":0.109389},{"month":7,"riseRate":0.5,"avgChangeRate":0.069459},{"month":8,"riseRate":0.5,"avgChangeRate":-0.024213},{"month":9,"riseRate":0,"avgChangeRate":-0.127435},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.025526},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058675},{"month":12,"riseRate":0.714286,"avgChangeRate":-0.023816}],"exchange":"SEHK","name":"复宏汉霖","nameEN":"HENLIUS"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复宏汉霖,02696,复宏汉霖股票,复宏汉霖股票老虎,复宏汉霖股票老虎国际,复宏汉霖行情,复宏汉霖股票行情,复宏汉霖股价,复宏汉霖股市,复宏汉霖股票价格,复宏汉霖股票交易,复宏汉霖股票购买,复宏汉霖股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复宏汉霖(02696)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复宏汉霖(02696)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}